Partnering

Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has formed a global co-development and commercialization pact with Theravance Biopharma, a South San Francisco, California-headquartered biopharmaceutical company, for…

Merck KGaA has partnered with Blue Mesa Health, a New York-headquartered digital therapeutics company, to pilot Blue Mesa’s diabetes-prevention programs in territories outside of the US. Blue Mesa Health has…

Eisai and the Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease (AD)-associated genetic variants on the behavior of brain cells, called…

AstraZeneca and Syndax Pharmaceuticals, a Waltham, Massachusetts-headquartered clinical-stage biopharmaceutical company developing cancer therapies, have formed a clinical pact to evaluate AstraZeneca’s durvalumab, a human monoclonal antibody directed against programmed death-ligand…

Boehringer Ingelheim (BI) has signed an outcomes-based contract with Prime Therapeutics, an Eagan, Minnesota-headquartered pharmacy benefit manager (PBM), for Jardiance (empagliflozin), a drug for treating Type II diabetes. The drug…

Shire and AB Biosciences, a Boston, Massachusetts-based biotechnology company, have signed a pact granting Shire an exclusive license to develop and commercialize AB Biosciences’ pan receptor interacting molecule (PRIM) program,…

Novartis and Spark Therapeutics, a Philadelphia, Pennsylvania-headquartered biopharmaceutical company, have signed a license pact to develop and commercialize investigational voretigene neparvovec, a vision-loss drug, outside the US while Spark Therapeutics…

Eisai has signed a licensing agreement with Adlai Nortye Biopharma, a Hangzhou, China-headquartered biopharmaceutical company, for E7046, Eisai’s investigational anticancer agent. Under the agreement, Adlai Nortye will have exclusive worldwide…

Pfizer has formed a clinical trial collaboration with Kite Pharma, Gilead Sciences’ cell-therapy subsidiary, to evaluate the investigational combination of Gilead’s Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor T cell…

Sandoz, the generics arm of Novartis, has partnered with Biocon, a Bangalore, India-based pharmaceutical company, to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology. Under the agreement, both…